Seungil Ro

Founder, Chief Scientific Officer at RosVivo Therapeutics

Dr. Seungil Ro Ph.D. is an Associate Professor and Principal Investigator at the University of Nevada in Reno, Nevada. He has researched gastrointestinal motility disorders and their molecular mechanisms for over 20 years. Dr. Ro is highly respected and published researcher. Dr. Ro has made some profound discoveries. He has identified key metabolic molecules responsible for the onset and development of Type 2 Diabetes (T2D). His studies have shown the depletion of these key metabolic molecules also leads to the development of obesity, fatty acid liver disease, gastroparesis and hyperlipidemia. His studies have shown the restoration of these endogenous molecules reverses these disease states. His work has resulted in multiple IPs and patents and the formation of RosVivo Therapeutics.


Org chart


Teams


Offices

This person is not in any offices


RosVivo Therapeutics

1 followers

RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. They're using unique scientific insights to develop a new pipeline of first-in-class drugs and diagnostic tests. Their development programs focus on the leading T2D, obesity, and COVID-19 drug candidates.


Industries

Employees

1-10

Links